KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Net Margin (2016 - 2025)

Supernus Pharmaceuticals has reported Net Margin over the past 15 years, most recently at 1.94% for Q4 2025.

  • Quarterly Net Margin fell 1074.0% to 1.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.37% through Dec 2025, down 1653.0% year-over-year, with the annual reading at 5.36% for FY2025, 1652.0% down from the prior year.
  • Net Margin was 1.94% for Q4 2025 at Supernus Pharmaceuticals, up from 23.49% in the prior quarter.
  • Over five years, Net Margin peaked at 21.91% in Q3 2024 and troughed at 23.49% in Q3 2025.
  • The 5-year median for Net Margin is 4.47% (2021), against an average of 4.92%.
  • Year-over-year, Net Margin soared 3232bps in 2024 and then crashed -4540bps in 2025.
  • A 5-year view of Net Margin shows it stood at 1.54% in 2021, then surged by 893bps to 15.24% in 2022, then tumbled by -95bps to 0.72% in 2023, then surged by 1131bps to 8.8% in 2024, then crashed by -122bps to 1.94% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Net Margin are 1.94% (Q4 2025), 23.49% (Q3 2025), and 13.58% (Q2 2025).